Dr Devoe on Safety and Efficacy Data for ELI-002 7P in KRAS+, MRD+ PDAC and CRC

Craig E. Devoe, MD, MS, discusses data for ELI-002 7P in patients with MRD-positive pancreatic and colorectal cancers after locoregional therapy.

Related Keywords

Craige Devoe , ,Oncology Service ,Rj Zuckerberg Cancer Center ,Division Of Medical Oncology ,Long Island Jewish Medical Center ,Shore University Hospital ,Medical Oncology ,Zuckerberg Cancer Center ,Hematology Oncology Service ,North Shore University ,